Literature DB >> 20473007

'Super high-flux' or 'high cut-off' hemofiltration and hemodialysis.

Toshio Naka, Michael Haase, Rinaldo Bellomo.   

Abstract

Recently, 'super high-flux' (SHF) or 'high cut-off' (HCO) membranes have been developed to increase the clearance of inflammatory mediators. In the experimental and clinical settings, SHF/HCO membranes appear to achieve greater clearance of inflammatory cytokines than conventional high-flux membranes. SHF/HCO membranes also restore immune cell function, attenuate hemodynamic instability and decrease plasma IL-6 levels. Moreover, SHF/HCO membranes can eliminate larger late-phase inflammatory mediators such as HMGB-1. Although albumin sieving coefficients with SHF/HCO membranes are greater than with conventional high-flux membranes, the daily amount lost is limited and can be replaced. Hemodialysis with SHF/HCO membranes can also achieve similar cytokine removal to hemofiltration with acceptable albumin losses. When strategies for sepsis or systemic inflammation treatment target middle molecular mediators, both SHF/HCO hemofiltration and hemodialysis appear feasible and safe and require further clinical investigation. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473007     DOI: 10.1159/000314871

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  17 in total

Review 1.  Enhancing dialyser clearance-from target to development.

Authors:  Kamonwan Tangvoraphonkchai; Andrew Davenport
Journal:  Pediatr Nephrol       Date:  2017-04-12       Impact factor: 3.714

Review 2.  The implications and management of septic acute kidney injury.

Authors:  Zaccaria Ricci; Andrea Polito; Angelo Polito; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2011-03-01       Impact factor: 28.314

Review 3.  Flummoxed by flux: the indeterminate principles of haemodialysis.

Authors:  Sudhir K Bowry; Fatih Kircelli; Madhukar Misra
Journal:  Clin Kidney J       Date:  2021-12-27

Review 4.  The membrane perspective of uraemic toxins: which ones should, or can, be removed?

Authors:  Sudhir K Bowry; Peter Kotanko; Rainer Himmele; Xia Tao; Michael Anger
Journal:  Clin Kidney J       Date:  2021-12-27

5.  Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments.

Authors:  Patrick M Honore; Rita Jacobs; Olivier Joannes-Boyau; Jouke De Regt; Willem Boer; Elisabeth De Waele; Vincent Collin; Herbert D Spapen
Journal:  Ann Intensive Care       Date:  2011-08-09       Impact factor: 6.925

6.  Clearance of serum solutes by hemofiltration in dogs with severe heat stroke.

Authors:  Guang-Ming Chen; Yu-Ying Lan; Cheng-Feng Wang; Hai-Xia Zhan; Wen-Rui Wang; Jin-Hua Chen; Jian Chen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-08-22       Impact factor: 2.953

7.  Hemodiafiltration Decreases Serum Levels of Inflammatory Mediators in Severe Leptospirosis: A Prospective Study.

Authors:  Sérgio Aparecido Cleto; Camila Eleutério Rodrigues; Ceila Maria Malaque; Jaques Sztajnbok; Antônio Carlos Seguro; Lúcia Andrade
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

8.  Effectiveness of High Cut-Off Hemofilters in the Removal of Selected Cytokines in Patients During Septic Shock Accompanied by Acute Kidney Injury-Preliminary Study.

Authors:  Grzegorz Kade; Arkadiusz Lubas; Agnieszka Rzeszotarska; Jolanta Korsak; Stanisław Niemczyk
Journal:  Med Sci Monit       Date:  2016-11-13

9.  Treatment of Acute Kidney Injury Complicating Septic Shock with EMiC2 High-cutoff Hemofilter: Case Series.

Authors:  Hoi-Ping Shum; King-Chung Chan; Wing-Wa Yan; Tak Mao Chan
Journal:  Indian J Crit Care Med       Date:  2017-11

10.  Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro.

Authors:  Björn Hegner; Theres Schaub; Daniel Janke; Daniel Zickler; Claudia Lange; Matthias Girndt; Joachim Jankowski; Ralf Schindler; Duska Dragun
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.